Effect of a Patient Support Program for Idiopathic Pulmonary Fibrosis Patients on Medication Persistence: A Retrospective Database Analysis

INTRODUCTION: In 2015, Boehringer Ingelheim (BI) created a support program for patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib, to help patients obtain their prescription, learn about their disease and medication, and provide support in the management of their IPF. The purp...

Descripción completa

Detalles Bibliográficos
Autores principales: Near, Aimee M., Burudpakdee, Chakkarin, Viswanathan, Shilpa, Kaila, Shuchita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280001/
https://www.ncbi.nlm.nih.gov/pubmed/34057677
http://dx.doi.org/10.1007/s12325-021-01768-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280001/
https://www.ncbi.nlm.nih.gov/pubmed/34057677
http://dx.doi.org/10.1007/s12325-021-01768-w

Ejemplares similares